Boeing Co vs Cassava Sciences Inc — how do they compare? Boeing Co trades at $233.17 (market cap $183.99B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Boeing Co is far larger — about 3853.2× Cassava Sciences Inc's market cap, and Boeing Co pays a 0.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BA | FLNA | |
|---|---|---|
Market Cap | $183.99B | $47.75M |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $4.64 |
52-Week Low | $179.12 | $0.87 |
Enterprise Value | $209.87B | -$34.93M |
Dividend Yield | 0.03% | — |
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $234.42, up 0.96% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $89.46 billion in 2025, turning a net profit of $2.24 billion after years of losses, though margins remain thin. Recent news highlights a strategic deal with Archer Aviation, transferring three subsidiaries for a 19.75% stake, potentially enhancing Boeing's position in autonomous flight technology.
The outlook is cautiously optimistic, with a consensus price target of $284 offering ~21% upside, but risks include high debt, regulatory scrutiny from FAA inspections, and volatile cash flows. Investors should weigh the recovery in commercial aerospace against execution challenges and macroeconomic headwinds.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Trailing returns across standard periods
Latest headlines on both assets
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →